Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy

Last updated: April 1, 2025
Sponsor: Peking University Cancer Hospital & Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Cancer

Treatment

HER2 expression of PET imaging

Clinical Study ID

NCT06909604
2019KT114-ZY02
  • Ages > 18
  • All Genders

Study Summary

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged ≥18 years old; ECOG 0 or 1;

  2. Patients with newly diagnosis HER2 positive or suspicious positive tumors;

  3. Receives neoadjuvant therapy

  4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;

  5. Life expectancy > 3 months -

Exclusion

Exclusion Criteria:

  1. Significant hepatic or renal dysfunction;

  2. Is pregnant or ready to pregnant;

  3. Cannot keep their states for half an hour;

  4. Refused to join the clinical research;

  5. Suffering from claustrophobia or other mental disorders;

  6. Any other situation that researchers considered it unsuitable to participate in thetrial.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: HER2 expression of PET imaging
Phase:
Study Start date:
January 01, 2025
Estimated Completion Date:
December 30, 2026

Connect with a study center

  • Peking University Cancer Hospital & Institute

    Beijing, 100142
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.